Antonis A. Armoundas, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Body Surface Potential Mapping | 14 | 2019 | 228 | 3.480 |
Why?
|
| Arrhythmias, Cardiac | 25 | 2023 | 2247 | 3.420 |
Why?
|
| Heart Conduction System | 18 | 2020 | 1006 | 3.030 |
Why?
|
| Electrocardiography | 25 | 2021 | 6404 | 2.590 |
Why?
|
| Tachycardia, Ventricular | 21 | 2022 | 1310 | 2.560 |
Why?
|
| Signal Processing, Computer-Assisted | 16 | 2020 | 1456 | 2.320 |
Why?
|
| Myocytes, Cardiac | 18 | 2020 | 1668 | 1.940 |
Why?
|
| Vagus Nerve Stimulation | 3 | 2023 | 228 | 1.780 |
Why?
|
| Mitochondria, Heart | 4 | 2018 | 227 | 1.770 |
Why?
|
| Models, Cardiovascular | 16 | 2017 | 978 | 1.560 |
Why?
|
| Membrane Potential, Mitochondrial | 4 | 2023 | 292 | 1.490 |
Why?
|
| Death, Sudden, Cardiac | 9 | 2019 | 1568 | 1.450 |
Why?
|
| Action Potentials | 13 | 2021 | 1838 | 1.450 |
Why?
|
| Electrocardiography, Ambulatory | 4 | 2020 | 582 | 1.430 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 5 | 2014 | 511 | 1.250 |
Why?
|
| Heart Rate | 11 | 2023 | 4204 | 1.170 |
Why?
|
| Heart | 13 | 2024 | 4414 | 1.090 |
Why?
|
| Monitoring, Physiologic | 3 | 2019 | 1792 | 1.080 |
Why?
|
| Cardiac Pacing, Artificial | 5 | 2021 | 881 | 1.070 |
Why?
|
| Sarcoplasmic Reticulum | 6 | 2016 | 164 | 1.040 |
Why?
|
| Calcium | 11 | 2019 | 5767 | 1.020 |
Why?
|
| Algorithms | 27 | 2024 | 14071 | 0.980 |
Why?
|
| American Heart Association | 3 | 2024 | 1047 | 0.950 |
Why?
|
| Catheter Ablation | 11 | 2021 | 2788 | 0.940 |
Why?
|
| Tidal Volume | 3 | 2019 | 519 | 0.900 |
Why?
|
| Swine | 18 | 2021 | 5988 | 0.890 |
Why?
|
| Myocardial Contraction | 2 | 2024 | 1515 | 0.870 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2023 | 969 | 0.840 |
Why?
|
| Fractals | 1 | 2023 | 124 | 0.790 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 4 | 2020 | 132 | 0.780 |
Why?
|
| Pulmonary Ventilation | 2 | 2014 | 377 | 0.780 |
Why?
|
| Artificial Intelligence | 4 | 2024 | 2659 | 0.770 |
Why?
|
| Myocardial Ischemia | 4 | 2023 | 2128 | 0.760 |
Why?
|
| Cardiovascular Diseases | 6 | 2024 | 15652 | 0.740 |
Why?
|
| Defibrillators, Implantable | 5 | 2015 | 1490 | 0.730 |
Why?
|
| Mitochondria | 5 | 2023 | 3673 | 0.730 |
Why?
|
| Monitoring, Ambulatory | 1 | 2024 | 357 | 0.710 |
Why?
|
| Refractory Period, Electrophysiological | 1 | 2020 | 40 | 0.700 |
Why?
|
| Photoplethysmography | 1 | 2020 | 66 | 0.690 |
Why?
|
| Ventricular Fibrillation | 5 | 2013 | 533 | 0.690 |
Why?
|
| Cardiac Resynchronization Therapy | 3 | 2024 | 562 | 0.680 |
Why?
|
| Respiratory Rate | 3 | 2019 | 179 | 0.660 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2021 | 170 | 0.630 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 6 | 2020 | 185 | 0.620 |
Why?
|
| Heart Atria | 3 | 2023 | 1363 | 0.620 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 254 | 0.590 |
Why?
|
| Oximetry | 1 | 2020 | 459 | 0.570 |
Why?
|
| Atrial Fibrillation | 4 | 2023 | 5189 | 0.530 |
Why?
|
| Heart Failure | 10 | 2024 | 11840 | 0.530 |
Why?
|
| Ventricular Function | 4 | 2009 | 403 | 0.520 |
Why?
|
| Heart Ventricles | 8 | 2020 | 3832 | 0.480 |
Why?
|
| Data Mining | 1 | 2020 | 562 | 0.470 |
Why?
|
| Bioelectric Energy Sources | 1 | 2014 | 15 | 0.460 |
Why?
|
| Sodium-Calcium Exchanger | 4 | 2016 | 91 | 0.450 |
Why?
|
| Guinea Pigs | 6 | 2018 | 1300 | 0.450 |
Why?
|
| Calcium Channels, L-Type | 2 | 2013 | 242 | 0.440 |
Why?
|
| Respiratory System | 1 | 2017 | 559 | 0.430 |
Why?
|
| Medicine | 1 | 2022 | 942 | 0.430 |
Why?
|
| Reactive Oxygen Species | 3 | 2018 | 2140 | 0.420 |
Why?
|
| Stroke Volume | 3 | 2024 | 5596 | 0.390 |
Why?
|
| Electric Countershock | 1 | 2015 | 534 | 0.390 |
Why?
|
| Animals | 46 | 2022 | 168764 | 0.380 |
Why?
|
| Calsequestrin | 3 | 2020 | 30 | 0.370 |
Why?
|
| Heart Diseases | 1 | 2024 | 2821 | 0.360 |
Why?
|
| Fourier Analysis | 1 | 2011 | 434 | 0.350 |
Why?
|
| Catecholamines | 2 | 2015 | 383 | 0.350 |
Why?
|
| Adenosine Triphosphate | 1 | 2017 | 1999 | 0.350 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 1896 | 0.340 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 1806 | 0.330 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 2020 | 698 | 0.330 |
Why?
|
| Oxygen | 1 | 2020 | 4241 | 0.310 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 1217 | 0.300 |
Why?
|
| Myocardial Infarction | 4 | 2023 | 11499 | 0.300 |
Why?
|
| Biological Clocks | 1 | 2010 | 320 | 0.290 |
Why?
|
| Up-Regulation | 2 | 2020 | 4137 | 0.290 |
Why?
|
| Receptors, Catecholamine | 1 | 2007 | 6 | 0.280 |
Why?
|
| Autonomic Nervous System | 4 | 2023 | 706 | 0.280 |
Why?
|
| Dogs | 7 | 2011 | 3822 | 0.260 |
Why?
|
| Primary Prevention | 1 | 2013 | 1187 | 0.250 |
Why?
|
| Stochastic Processes | 4 | 2017 | 358 | 0.250 |
Why?
|
| Lung | 3 | 2014 | 10033 | 0.250 |
Why?
|
| Energy Metabolism | 1 | 2017 | 2892 | 0.250 |
Why?
|
| Humans | 54 | 2024 | 765968 | 0.240 |
Why?
|
| Reproducibility of Results | 10 | 2022 | 20124 | 0.240 |
Why?
|
| Computer Simulation | 12 | 2013 | 6255 | 0.230 |
Why?
|
| Quality Improvement | 1 | 2020 | 3853 | 0.230 |
Why?
|
| Stroke | 2 | 2024 | 9747 | 0.230 |
Why?
|
| Risk Assessment | 8 | 2013 | 24282 | 0.230 |
Why?
|
| Myocardium | 4 | 2015 | 4760 | 0.230 |
Why?
|
| Disease Models, Animal | 9 | 2021 | 18293 | 0.230 |
Why?
|
| Time Factors | 8 | 2021 | 40065 | 0.230 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 1275 | 0.230 |
Why?
|
| Coronary Artery Disease | 1 | 2023 | 6544 | 0.220 |
Why?
|
| Surgery, Computer-Assisted | 3 | 2013 | 993 | 0.220 |
Why?
|
| Nonlinear Dynamics | 4 | 2016 | 490 | 0.210 |
Why?
|
| Predictive Value of Tests | 9 | 2014 | 15398 | 0.200 |
Why?
|
| Electrodes | 2 | 2016 | 609 | 0.200 |
Why?
|
| Pericardium | 1 | 2006 | 679 | 0.200 |
Why?
|
| Models, Biological | 4 | 2018 | 9443 | 0.190 |
Why?
|
| Potassium Channels | 4 | 2008 | 534 | 0.190 |
Why?
|
| Mitochondrial Membranes | 1 | 2023 | 184 | 0.190 |
Why?
|
| Signal Transduction | 6 | 2018 | 23601 | 0.180 |
Why?
|
| Ventricular Remodeling | 2 | 2015 | 1272 | 0.180 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2012 | 2136 | 0.180 |
Why?
|
| Electrophysiological Phenomena | 2 | 2014 | 307 | 0.180 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 8923 | 0.180 |
Why?
|
| Vagus Nerve | 1 | 2023 | 460 | 0.180 |
Why?
|
| Electrophysiology | 3 | 2003 | 1263 | 0.170 |
Why?
|
| Technology Transfer | 1 | 2020 | 41 | 0.170 |
Why?
|
| Calcium Signaling | 3 | 2020 | 733 | 0.170 |
Why?
|
| Wireless Technology | 1 | 2020 | 99 | 0.170 |
Why?
|
| Torsades de Pointes | 1 | 2000 | 78 | 0.160 |
Why?
|
| Random Allocation | 2 | 2014 | 2395 | 0.160 |
Why?
|
| Potassium Channels, Voltage-Gated | 3 | 2005 | 142 | 0.160 |
Why?
|
| Models, Animal | 3 | 2014 | 2120 | 0.160 |
Why?
|
| Ion Channels | 2 | 2015 | 1045 | 0.160 |
Why?
|
| Sensitivity and Specificity | 8 | 2014 | 14652 | 0.150 |
Why?
|
| Sus scrofa | 1 | 2020 | 430 | 0.150 |
Why?
|
| Male | 25 | 2021 | 363698 | 0.150 |
Why?
|
| Computers | 1 | 2020 | 588 | 0.150 |
Why?
|
| Muscle Cells | 2 | 2011 | 194 | 0.150 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2020 | 265 | 0.140 |
Why?
|
| Disease-Free Survival | 4 | 2015 | 6832 | 0.140 |
Why?
|
| Oxidative Stress | 2 | 2023 | 3141 | 0.130 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 4247 | 0.130 |
Why?
|
| Cardiovascular System | 1 | 2024 | 841 | 0.130 |
Why?
|
| Polysomnography | 1 | 2023 | 1859 | 0.130 |
Why?
|
| Heart Function Tests | 1 | 2017 | 317 | 0.130 |
Why?
|
| Models, Genetic | 1 | 2006 | 3449 | 0.120 |
Why?
|
| Homeostasis | 1 | 2007 | 3336 | 0.120 |
Why?
|
| Periodicity | 1 | 2017 | 345 | 0.120 |
Why?
|
| Hand | 1 | 2020 | 909 | 0.120 |
Why?
|
| Information Dissemination | 1 | 2023 | 1142 | 0.120 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2015 | 242 | 0.120 |
Why?
|
| Pyruvic Acid | 1 | 2015 | 205 | 0.110 |
Why?
|
| Organelles | 1 | 2016 | 264 | 0.110 |
Why?
|
| Permeability | 1 | 2016 | 726 | 0.110 |
Why?
|
| Cardiology | 1 | 2024 | 1702 | 0.110 |
Why?
|
| Cyclosporine | 1 | 2016 | 778 | 0.110 |
Why?
|
| Oxidation-Reduction | 2 | 2016 | 2218 | 0.100 |
Why?
|
| Brugada Syndrome | 1 | 2013 | 97 | 0.100 |
Why?
|
| Models, Anatomic | 3 | 2008 | 677 | 0.100 |
Why?
|
| Respiratory Function Tests | 1 | 2017 | 1693 | 0.100 |
Why?
|
| Exercise Test | 1 | 2020 | 2180 | 0.100 |
Why?
|
| Cells, Cultured | 5 | 2020 | 18973 | 0.100 |
Why?
|
| Endotoxemia | 1 | 2013 | 198 | 0.100 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 1966 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2021 | 65188 | 0.090 |
Why?
|
| Ventricular Function, Left | 1 | 2024 | 3928 | 0.090 |
Why?
|
| Kv Channel-Interacting Proteins | 2 | 2008 | 39 | 0.090 |
Why?
|
| Electricity | 1 | 2011 | 174 | 0.090 |
Why?
|
| Models, Statistical | 2 | 2003 | 5089 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2018 | 2721 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 1 | 2018 | 2627 | 0.090 |
Why?
|
| Sodium | 2 | 2008 | 1591 | 0.090 |
Why?
|
| Papillary Muscles | 1 | 2010 | 192 | 0.080 |
Why?
|
| Calcium-Binding Proteins | 3 | 2015 | 1077 | 0.080 |
Why?
|
| Lactic Acid | 1 | 2015 | 1137 | 0.080 |
Why?
|
| Fluorescent Dyes | 1 | 2018 | 1930 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2014 | 1187 | 0.080 |
Why?
|
| Metabolome | 1 | 2016 | 1005 | 0.080 |
Why?
|
| Adipose Tissue, Brown | 1 | 2015 | 776 | 0.080 |
Why?
|
| Survival Rate | 2 | 2015 | 12795 | 0.080 |
Why?
|
| Cytosol | 1 | 2011 | 885 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3800 | 0.070 |
Why?
|
| Axons | 1 | 2016 | 1682 | 0.070 |
Why?
|
| Brain Ischemia | 1 | 2021 | 3000 | 0.070 |
Why?
|
| Cardiomyopathies | 2 | 2015 | 2067 | 0.070 |
Why?
|
| Ablation Techniques | 1 | 2010 | 254 | 0.070 |
Why?
|
| United States | 3 | 2024 | 72903 | 0.070 |
Why?
|
| Sleep | 1 | 2023 | 4813 | 0.070 |
Why?
|
| Catheters | 2 | 2021 | 426 | 0.070 |
Why?
|
| Organometallic Compounds | 1 | 2010 | 644 | 0.070 |
Why?
|
| Reference Values | 2 | 2012 | 4908 | 0.070 |
Why?
|
| Long QT Syndrome | 2 | 2002 | 474 | 0.070 |
Why?
|
| Synapses | 1 | 2016 | 1754 | 0.070 |
Why?
|
| Mutation | 3 | 2015 | 30198 | 0.070 |
Why?
|
| Middle Aged | 7 | 2021 | 223009 | 0.070 |
Why?
|
| Nitric Oxide | 1 | 2015 | 2143 | 0.070 |
Why?
|
| Sodium Channels | 1 | 2008 | 334 | 0.070 |
Why?
|
| Female | 12 | 2021 | 396112 | 0.060 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2024 | 4628 | 0.060 |
Why?
|
| Thorax | 2 | 2006 | 554 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2013 | 1957 | 0.060 |
Why?
|
| Prognosis | 4 | 2012 | 29922 | 0.060 |
Why?
|
| Isoproterenol | 2 | 2015 | 398 | 0.060 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2006 | 199 | 0.060 |
Why?
|
| Ethanol | 1 | 2010 | 1323 | 0.060 |
Why?
|
| Physicians | 1 | 2022 | 4588 | 0.050 |
Why?
|
| Aged | 6 | 2021 | 171117 | 0.050 |
Why?
|
| Inflammation | 1 | 2023 | 10850 | 0.050 |
Why?
|
| Software | 1 | 2018 | 4462 | 0.050 |
Why?
|
| Rabbits | 2 | 2006 | 4734 | 0.050 |
Why?
|
| Glucose | 1 | 2015 | 4335 | 0.050 |
Why?
|
| Recurrence | 2 | 2010 | 8501 | 0.050 |
Why?
|
| Sheep, Domestic | 1 | 2022 | 52 | 0.050 |
Why?
|
| Tachycardia | 1 | 2005 | 594 | 0.050 |
Why?
|
| Quality of Life | 1 | 2024 | 13462 | 0.050 |
Why?
|
| Mitral Valve | 1 | 2010 | 1476 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 2 | 2008 | 2686 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6499 | 0.050 |
Why?
|
| Disease Susceptibility | 2 | 1998 | 1789 | 0.040 |
Why?
|
| Pacemaker, Artificial | 1 | 2006 | 827 | 0.040 |
Why?
|
| Abdomen | 1 | 2006 | 1134 | 0.040 |
Why?
|
| Bundle-Branch Block | 1 | 2002 | 280 | 0.040 |
Why?
|
| Quality Control | 1 | 2003 | 837 | 0.040 |
Why?
|
| Reperfusion | 1 | 2021 | 267 | 0.040 |
Why?
|
| Mice | 5 | 2021 | 81819 | 0.040 |
Why?
|
| Reoperation | 1 | 2010 | 4294 | 0.040 |
Why?
|
| Sheep | 1 | 2022 | 1440 | 0.040 |
Why?
|
| RNA Interference | 1 | 2008 | 2832 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2003 | 760 | 0.040 |
Why?
|
| Diastole | 1 | 2021 | 785 | 0.040 |
Why?
|
| Neurons | 1 | 2018 | 9525 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2008 | 3432 | 0.040 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2021 | 485 | 0.040 |
Why?
|
| Disease Progression | 1 | 2014 | 13632 | 0.030 |
Why?
|
| Adult | 4 | 2020 | 223044 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2003 | 2352 | 0.030 |
Why?
|
| Wavelet Analysis | 1 | 2016 | 56 | 0.030 |
Why?
|
| Baroreflex | 1 | 1997 | 153 | 0.030 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2015 | 88 | 0.030 |
Why?
|
| Shal Potassium Channels | 2 | 2005 | 20 | 0.030 |
Why?
|
| Models, Neurological | 1 | 2003 | 1747 | 0.030 |
Why?
|
| Spectrum Analysis | 1 | 1997 | 443 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2015 | 10070 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2015 | 8278 | 0.030 |
Why?
|
| Data Collection | 1 | 2023 | 3318 | 0.030 |
Why?
|
| KCNQ Potassium Channels | 2 | 2005 | 15 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 59889 | 0.030 |
Why?
|
| Databases as Topic | 1 | 2016 | 471 | 0.030 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2015 | 345 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 22332 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 39193 | 0.030 |
Why?
|
| Hypertrophy | 1 | 2015 | 559 | 0.030 |
Why?
|
| KCNQ1 Potassium Channel | 2 | 2005 | 103 | 0.030 |
Why?
|
| Markov Chains | 1 | 2016 | 968 | 0.030 |
Why?
|
| Systems Biology | 1 | 2016 | 481 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 612 | 0.030 |
Why?
|
| Guanylate Cyclase | 1 | 2013 | 205 | 0.030 |
Why?
|
| Phantoms, Imaging | 2 | 2013 | 2475 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 15880 | 0.020 |
Why?
|
| Cyclic GMP | 1 | 2013 | 394 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2015 | 1644 | 0.020 |
Why?
|
| Cardiotonic Agents | 1 | 2015 | 538 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2003 | 5302 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2016 | 798 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2024 | 3850 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2006 | 4958 | 0.020 |
Why?
|
| Risk Factors | 2 | 2012 | 74840 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2016 | 2477 | 0.020 |
Why?
|
| Peptides | 1 | 2003 | 4331 | 0.020 |
Why?
|
| Linear Models | 2 | 1999 | 5876 | 0.020 |
Why?
|
| Troponin I | 1 | 2015 | 655 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2021 | 2674 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 54802 | 0.020 |
Why?
|
| Sarcomeres | 1 | 2013 | 379 | 0.020 |
Why?
|
| Potassium | 2 | 2005 | 1311 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 59489 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 8041 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2015 | 975 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2015 | 14448 | 0.020 |
Why?
|
| Cysteine | 1 | 2013 | 898 | 0.020 |
Why?
|
| Swine, Miniature | 1 | 2010 | 971 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2008 | 267 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2008 | 368 | 0.020 |
Why?
|
| Fibrosis | 1 | 2015 | 2070 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2010 | 15747 | 0.020 |
Why?
|
| Injections | 1 | 2010 | 840 | 0.020 |
Why?
|
| Blood Pressure | 3 | 2015 | 8532 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 2453 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2008 | 918 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 2216 | 0.020 |
Why?
|
| Kv1.4 Potassium Channel | 1 | 2005 | 3 | 0.020 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2005 | 72 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2008 | 939 | 0.010 |
Why?
|
| Body Weight | 1 | 2015 | 4622 | 0.010 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2005 | 145 | 0.010 |
Why?
|
| Flecainide | 1 | 2003 | 41 | 0.010 |
Why?
|
| Gene Expression Regulation | 2 | 2015 | 11888 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 9550 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2008 | 2669 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2015 | 5993 | 0.010 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2010 | 1414 | 0.010 |
Why?
|
| Gene Expression | 2 | 2005 | 7584 | 0.010 |
Why?
|
| Equipment Design | 1 | 2008 | 3481 | 0.010 |
Why?
|
| CHO Cells | 1 | 2002 | 1372 | 0.010 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2003 | 769 | 0.010 |
Why?
|
| Species Specificity | 1 | 2003 | 2406 | 0.010 |
Why?
|
| Renal Circulation | 1 | 1999 | 289 | 0.010 |
Why?
|
| Cricetinae | 1 | 2002 | 2411 | 0.010 |
Why?
|
| Rats | 2 | 2008 | 23707 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4562 | 0.010 |
Why?
|
| Animals, Genetically Modified | 1 | 2002 | 1560 | 0.010 |
Why?
|
| Blood Circulation | 1 | 1997 | 248 | 0.010 |
Why?
|
| Lung Volume Measurements | 1 | 1997 | 381 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 15543 | 0.010 |
Why?
|
| Transfection | 1 | 2002 | 5743 | 0.010 |
Why?
|
| Feedback | 1 | 1997 | 796 | 0.010 |
Why?
|
| Posture | 1 | 1997 | 954 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 2003 | 3096 | 0.010 |
Why?
|
| Artifacts | 1 | 1999 | 1893 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 12768 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1998 | 81514 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1999 | 8102 | 0.000 |
Why?
|
| Phenotype | 1 | 2003 | 16721 | 0.000 |
Why?
|